2019 Multidisciniplary NET Disease Symposium
North American Neuroendocrine Tumor Society (NANETS)
ESMO 2019 Annual Congress
European Society for Medical Oncology (ESMO)
2019 SNMMI Annual Meeting
Society of Nuclear Medicine and Medical Imaging (SNMMI)
2019 ASCO Annual Meeting
American Society of Clinical Oncology (ASCO)
Congrès National GTE (Groupe d’études des Tumeurs Neuroendocrines) 2018
Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
AAA today announced that it has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. LUTATHERA®, which received orphan drug designation from the FDA, is a first-in-class drug and the first available FDA-approved Peptide Receptor Radioisotope Therapy (PRRT), a form of targeted treatment comprising a targeting molecule that carries a radioactive component.